Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
20 January, 2019 19:30 IST
Cipla gets USFDAs final approval for generic Isuprel
Source: IRIS | 14 Jun, 2018, 10.36AM
Comments  |  Post Comment

Cipla, announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Isoproterenol Hydrochloride Injection USP, 0.2mg/mL, single-use sterile Ampoule from the United States Food and Drug Administration (US FDA).

Cipla's Isoproterenol Hydrochloride Injection USP, 0.2mg/mL, ampoule is APrated generic therapeutic equivalent version of Hospira Inc's Isuprel Injection, 0.2mg/ml and is indicated for the treatment of…

> Mild or transient episodes of heart block that do not require electric shock or pacemaker therapy.

> Serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation).

> Use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available.

> Bronchospasm occurring during anesthesia.

> As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock.

According to IQVIA (IMS Health), Isuprel Injection and its generic equivalents had US sales of approximately USD 148M for the 12-month period ending April 2018.

Shares of the company gained Rs 18.9, or 3.33%, to trade at Rs 585.95. The total volume of shares traded was 75,241 at the BSE (10.22 a.m., Thursday).





Cipla Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Ratnamani Metals & Tubes receives order worth Rs 2 bn - 18-Jan-2019 15:59
Aurobindo Pharma to acquire portfolio of oncology injectables products - 18-Jan-2019 13:47
Reliance Ind Q3 earnings up 8.8%; GRM's at USD 8.8/bbl - 18-Jan-2019 13:08
Announcement under Regulation 30 (LODR)-Change in Directorate - 18-Jan-2019 11:14
Zydus receives final approval for Acetazolamide ER capsules - 17-Jan-2019 13:27
OnMobile Global renews its contract with Telefonica Moviles Espana, SAU (Telefonica) - 17-Jan-2019 10:14
Suven Life Sciences secures 2 overseas product patents - 16-Jan-2019 13:45
Texmaco Rail & Engineering receives orders worth Rs 2.62 bn - 16-Jan-2019 12:59
Dr Reddy's announces completion of USFDA audit of formulation facility - 16-Jan-2019 10:15
L&T Hydrocarbon consortium wins EPCI order from Saudi Aramco - 15-Jan-2019 10:24
Zydus Cadila gets final approval from USFDA for 2 drugs - 15-Jan-2019 10:20
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer